Table 2.
Intensive-care management and outcomes of patients with severe SARS-CoV-2 infection (n = 413) during intensive-care-unit stay, according to SARS-CoV-2 variants.
| Preexisting Variants | Alpha (B.1.1.7) |
Other Variants |
p-Values | ||||
|---|---|---|---|---|---|---|---|
| N = 183 | N = 197 | N = 33 | Global Comparison | Preexisting vs. Alpha a | Preexisting vs. Others a | Alpha vs. Others a | |
| Invasive MV | 125 (68.3%) | 120 (60.9%) | 22 (66.7%) | 0.312 | - | - | - |
| MV duration, days | 16 (9;27) | 14 (8;23) | 16.5 (10;30) | 0.362 | - | - | - |
| ECMO support | 29 (15.8%) | 19 (9.6%) | 6 (18.2%) | 0.133 | - | - | - |
| Duration of ECMO, days | 17.0 (6.0;31.0) | 12.0 (4.0;17.0) | 34.5 (8.0;55.0) | 0.186 | - | - | - |
| Vasopressor support | 87 (47.5%) | 94 (47.7%) | 17 (51.5%) | 0.912 | - | - | - |
| Duration of vasopressors, days | 7 (3;15) | 9 (4;16) | 9 (3;14) | 0.862 | - | - | - |
| RRT | 47 (25.7%) | 53 (26.9%) | 7 (21.2%) | 0.784 | - | - | - |
| Pulmonary thrombosis | 10 (5.5%) | 11 (5.6%) | 1 (3.0%) | 1.000 | - | - | - |
| VAP | 88 (48.1%) | 85 (43.4%) | 15 (45.5%) | 0.654 | - | - | - |
| Dexamethasone | 143 (78.1%) | 168 (85.3%) | 31 (93.9%) | 0.038 | 0.199 | 0.101 | 0.444 |
| Tocilizumab | 6 (3.3%) | 25 (12.7%) | 4 (12.1%) | 0.002 | 0.003 | 0.139 | 1.000 |
| Day-28 mortality | 57 (31.1%) | 51 (26.2%) | 10 (30.3%) | 0.550 | - | - | - |
| Day-90 mortality | 74 (40.4%) | 61 (31.6%) | 13 (39.4%) | 0.189 | - | - | - |
a Pairwise comparisons applying a Sidak correction to account for multiple testing. MV: mechanical ventilation; ECMO: extracorporeal membrane oxygenation; RRT: renal replacement therapy; VAP: ventilator-acquired pneumonia.